A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513639-26-00

Acronym

WN45319

Enrollment

Registered

2024-10-14

Start date

Unknown

Completion date

2025-03-18

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis (MS)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Belgium, Czechia, France, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026